Milestone Pharmaceuticals Inc. (NasdaqGS: MIST)
Health Care · Pharmaceuticals · CA
$1.19
+12.80% today · -37.6% 1Y
Milestone Pharmaceuticals Inc. (NasdaqGS: MIST) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $148.66M and employs 38 people.
Over the last twelve months the share price has lost 37.6%, trading between 1.00 and 3.06.
Tweenvest scores Milestone Pharmaceuticals Inc. across four factors: quality 23/100, value 37/100. Its strongest factor is value.
MIST price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $148.66M
- Revenue (TTM)
- $2.34M
- P/E
- —
- EPS
- -0.71
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- $3.06
- 52-week low
- $1.00
- Avg volume (3M)
- —
- Shares outstanding
- 140.91M
- Employees
- 38
- Next earnings
- —
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
- ISIN
- CA59935V1076
- Founded
- 2003
- Listed since
- May 9, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,231.78 | -0.15% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $272.81 | -0.12% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF371.90 | -0.51% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.29 | -1.18% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.